CORRECTED - Moody's weighs ratings as drug-patent lapses near

(Reuters) - NEW YORK, July 10 - Moody's Investors Service on
Tuesday said a wave of patent expirations on blockbuster drugs
between 2010 and 2012 could lead it to begin lowering its
credit ratings on a number of large U.S. drugmakers several
years before then.




Eli Lilly and Co. , Pfizer Inc. and
Bristol-Myers Squibb Co. are particularly vulnerable to
the downgrades because the top-selling drug of each expires in
that period.


Read more at Reuters.com Government Filings News